CD19 and acute lymphoblastic leukemia: However, two ALL clinical trials, one on pediatric patients and the other on adults with the same low-affinity CAR-T cell product (named CAT), have not prevented CD-19-negative relapses from occurring in five out of 12 children and two out of 20 adults, respectively (96, 97).